12
Participants
Start Date
June 1, 2024
Primary Completion Date
October 1, 2024
Study Completion Date
October 20, 2024
Immunohistochemistry
This intervention will specifically focus on evaluating the role of ENPP1 in bladder cancer patients, distinguishing it from other interventions by targeting immune evasion and chemoresistance pathways. The intervention will include a combination of targeted molecular therapies and immunotherapy, aimed at assessing the therapeutic potential of ENPP1 inhibition in improving treatment outcomes for bladder cancer patients. This differs from previous studies by integrating advanced biomarker analysis and personalized treatment approaches based on ENPP1 expression levels.
Lanzhou University Second Hospital, Lanzhou
Lanzhou University Second Hospital
OTHER